MYC and adrenal cortex carcinoma: The high-risk type of ACC-I showed substantial overexpression of MYC and MYC target genes, mRNA splicing, and enrichment for NOTCH-activating mutations, resulting in shorter median survival than patients with ACC-II (3.44 years vs. 23.2 years) (9).